IPSC NASDAQ
Century Therapeutics, Inc.
1W: -8.4%
1M: -27.5%
3M: -36.2%
YTD: +53.8%
1Y: +206.1%
3Y: -24.3%
5Y: -93.4%
$1.53
-0.08 (-4.97%)
Weekly Expected Move ±6.8%
$1
$1
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (33)
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
Analysts Set Century Therapeutics, Inc. (NASDAQ:IPSC) PT at $4.75
Bank of New York Mellon Corp Takes $733,000 Position in Century Therapeutics, Inc. $IPSC
HC Wainwright Issues Pessimistic Forecast for IPSC Earnings
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
Graham, Appian And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
Lowe's, ZTO Express, Viavi Solutions And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Century Therapeutics GAAP EPS of -$0.11 beats by $0.06
Century Therapeutics Reports First Quarter Financial Results and Business Updates
Analysts Set Century Therapeutics, Inc. (NASDAQ:IPSC) Target Price at $4.00
Q1 Earnings Forecast for IPSC Issued By HC Wainwright
Top and lowest-rated small-cap stocks heading into earnings
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) PT at $3.50
Top performing small-cap stocks YTD as volatility hits markets
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Increases By 33.6%
Small-Cap healthcare stocks ranked by quant ratings after earnings season
Century Therapeutics GAAP EPS of -$0.14, revenue of $109.2M
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) PT at $3.80
Century Therapeutics to Participate in Upcoming Investor Conferences in March
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Century Therapeutics: A Very Promising Contender In The Type I Diabetes Mellitus Functional Cure Race
Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference